Wrn inhibitor

A compound of Formula (I), or a pharmaceutically acceptable salt, isotopic variant, tautomer or stereoisomer thereof, or a mixture thereof:

• wherein,
• X and Y are each independently selected from CH and N, and at least one of X and Y is N atom;
• Ring A is absent or selected from C3-10 cycloalkyl, 5-10 membered heteroaryl, 5-10 membered heterocyclyl, and C6-10 aryl;
• R1 is selected from 5-12 membered heteroaryl and 5-12 membered heterocyclyl, and the R1 is optionally substituted with 1, 2, 3, 4 or 5 Rx, provided that R1 is not pyridyl or
• Rx is selected from H, D, halogen, NH2, CN, OH, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, —C(O)Ra, —C(O)ORa, —OC(O)Ra, —C(O)NH—Ra, —NHC(O)—Ra, —(CH2)p—ORa, —(CH2)p—C(O)Ra, —P(O)—(Ra)2, and —S(O)2—Ra, wherein Ra is selected from H, C1-6 alkyl, C1-6 haloalkyl and C3-6 cycloalkyl, and p is selected from 0, 1, 2, 3 and 4;
• or two Rx on the same atom are taken together to form oxo or thio;
• R2 is selected from H, D, halogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 alkylthio, and C3-6 cycloalkyl;
• R3 is selected from H, D, halogen, NH2, CN, OH, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C3-6 cycloalkyl, or R3 on two different carbon atoms are connected to form a bridged ring, or two R3 on the same carbon atom are connected to form C3-10 cycloalkyl, 5-10 membered heteroaryl, C3-10 cycloalkyl or 3-10 membered heterocyclyl;
• R4 is selected from H, D, halogen, NHs, CN, OH, SF5, SCF3, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkylthio, C3-10 cycloalkyl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl, and C6-10 aryl;
• R5 is selected from H, D, halogen, NHs, CN, OH, C1-6 alkyl, C1-6 deuterated alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 alkylthio, and C3-6 cycloalkyl;
• m is selected from 0, 1, 2, 3, 4 and 5;
• n is selected from 0, 1, 2, 3, 4, 5, 6, 7 and 8;
• R1-R5 are optionally deuterated, up to fully deuterated.